激动剂陷阱揭秘:68Ga-DOTANOC子宫肌瘤假阳性经68Ga-NODAGA-JR11拮抗剂PET澄清
一例22岁神经内分泌肿瘤女性患者行68Ga-DOTANOC PET/CT时发现子宫肌瘤摄取,类似盆腔转移。随后68Ga-NODAGA-JR11拮抗剂PET/CT显示肿瘤仍可检出而肌瘤无摄取,证实为良性平滑肌瘤;激动剂因内化滞留而假阳性,拮抗剂仅表面结合避免非特异性蓄积。
要点
- 激动剂SSTR PET可因子宫内化滞留出现假阳性,模拟NET转移。
- 拮抗剂SSTR PET无肌瘤摄取,可澄清诊断并避免不必要干预。
- 双SSTR显像可提升诊断确定性并优化诊疗一体化。
核心结论
- 68Ga-DOTANOC激动剂PET中子宫肌瘤摄取为假阳性,68Ga-NODAGA-JR11拮抗剂PET可明确排除。
研究设计与样本
- 个案报道:一例22岁神经内分泌肿瘤女性患者依次行68Ga-DOTANOC与68Ga-NODAGA-JR11 PET/CT。
主要发现
- 68Ga-DOTANOC PET/CT显示子宫肌瘤摄取,与低级别NET沉积难以区分。
- 68Ga-NODAGA-JR11 PET/CT保留肿瘤检出但肌瘤无摄取,证实为良性平滑肌瘤。
关键数值与推荐
- 激动剂在雌激素致敏肌瘤中经SSTR2内化导致DOTANOC滞留延长,拮抗剂仅表面结合无特异蓄积。
- 肌瘤缺乏拮抗剂结合归因于受体密度不足支持持续表面结合。
临床怎么用
- 对SSTR激动剂PET盆腔局灶摄取存疑时,可考虑拮抗剂SSTR PET澄清,避免误判转移。
局限性
- 单例个案报道,结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 22-year-old woman with a neuroendocrine tumor underwent 68 Ga-DOTANOC PET/CT, revealing incidental uterine fibroid uptake mimicking pelvic metastasis. The fibroid's hyperavidity posed diagnostic ambiguity, indistinguishable from low-grade NET deposits. Crucially, subsequent 68 Ga-NODAGA-JR11 (SSTR antagonist) PET/CT demonstrated preserved tumor detection but absent fibroid uptake, unequivocally confirming benign leiomyoma. This striking discordance unveils agonists' internalization trap-prolonged DOTANOC retention through SSTR2 endocytosis in estrogen-primed fibroids-versus antagonists' precision: surface binding without non-specific accumulation. In fibroids, the lack of antagonist binding-despite agonist positivity-arises from inadequate receptor density to support sustained surface binding, thereby eliminating false-positive results. Dual SSTR imaging redefines diagnostic certainty, averting interventions while optimizing theranostics.
引用
- Taggar M, Shamim SA, Jain R, et al. Agonist Trap Unmasked: 68 Ga-DOTANOC Fibroid Mimicry Resolved by 68 Ga-NODAGA-JR11 Antagonist PET. Clin Nucl Med. 2026. PMID: 42149618. doi:10.1097/RLU.0000000000006506
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。